ROSM uses research-based methods to lead patients back to full function and health. Our team is dedicated to providing effective, minimally-invasive options to maintain and enhance our patients’ quality of life. Please review these studies for more information on our treatment modalities. If you have any further questions, do not hesitate to contact us.
Improved Hip Function and Pain Alleviation after Single Administration of Platelet Rich Plasma for Hip Labral Tears: A Prospective Cohort Study
Prospective cohort pilot study to assess the efficacy of ultrasound guided platelet rich plasma (PRP) injections in the non-operative management of acetabular hip labral tears.
Methods Study and Design
Patients were diagnosed with hip labral tears via magnetic resonance imaging/arthrogram (MRI/MRA) and also with ultrasound. Institutional Review Board (IRB) approval was gained for a prospective cohort pilot study of eight patients (N=8). Study patients, after all failing conservative management (i.e., physical therapy, oral pain medications) received ultrasound guided injection of PRP into their hip joints at the site of labral injury. Using the Harris Hip Score (HHS) and the Visual Analogue Scale (VAS), we characterized changes in overall patient function and hip pain at baseline, 2, 6, and 8 weeks after PRP administration, as well as post-injury imaging via ultrasound at 2, 6, and 8 weeks, and final MRI/MRA imaging after completion of the study (>8 weeks).
Statistically significant differences in HHS were seen 2,6, and 8 weeks after injection of PRP for hip labral tears as compared to baseline . Corresponding statistically significant improvements were also seen in VAS both at rest and with activity at 2,6 , and 8 weeks after PRP injection compared to baseline. Significant improvements in morphology were seen including substantial repair of labral tears after ultrasound imaging and MRI/MRA.
PRP is a non-surgical treatment option for patients with hip labral tears which reduces hip pain, promotes hip labrum repair, and improves function beginning in as little as two weeks after administration.
Ultrasound-Guided Injection of Platelet-Rich Plasma and Hyaluronic Acid, Separately and in Combination, for Hip Osteoarthritis: A Randomized Controlled Study
The effectiveness of intra-articular platelet-rich plasma (PRP) injections has been evaluated in knee chondroplasty and osteoarthritis (OA); however, little evidence of its efficacy in hip OA exists.
To compare the therapeutic efficacy of autologous PRP, hyaluronic acid (HA), or a combination of both (PRP1HA) in hip OA.
Patients aged between 18 and 65 years who were treated with outpatient surgery and who had hip OA and pain intensity at baseline of .20 on a 100-mm visual analog scale (VAS) were recruited for this study. Exclusion criteria were extensive surgery; presence of excessive deformities; or rheumatic, infective, cardiovascular, or immune system disorders. The primary outcome measure was a change in pain intensity as assessed by the VAS at 2, 6, and 12 months after treatment. Secondary outcome measures were the Harris Hip Score, Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), and concentration of growth factors in PRP and their correlation with clinical outcomes. Clinical outcomes were evaluated by assessors and collectors blinded to the type of treatment administered.
A total of 111 patients were randomly assigned to 3 groups and received 3 weekly injections of either PRP (44 patients), PRP1HA (31 patients), or HA (36 patients). At all follow-ups, the PRP group had the lowest VAS scores. In particular, at 6-month follow-up, the mean VAS score was 21 (95% CI, 15-28) in the PRP group, 35 (95% CI, 26-45) in the PRP1HA group, and 44 (95% CI, 36-52) in the HA group (P\.0005 [PRP vs HA] and P = .007 [PRP vs PRP1HA]; F = 0.663). The WOMAC score of the PRP group was significantly better at 2-month follow-up (mean, 73; 95% CI, 68-78) and 6-month follow-up (mean, 72; 95% CI, 67-76) but not at 12-month follow-up. A significant, ‘‘moderate’’ correlation was found between interleukin-10 and variations of the VAS score (r = 0.392; P = .040). Significant improvements were achieved in reducing pain and ameliorating quality of life and functional recovery.
Results indicated that intra-articular PRP injections offer a significant clinical improvement in patients with hip OA without relevant side effects. The benefit was significantly more stable up to 12 months as compared with the other tested treatments. The addition of PRP1HA did not lead to a significant improvement in pain symptoms.
Click here to read the full article.